Achillion Pharmaceuticals, Inc.  

(Public, NASDAQ:ACHN)   Watch this stock  
Find more results for ACHN
7.09
-0.30 (-4.06%)
After Hours: 7.08 -0.01 (-0.14%)
Sep 1, 6:58PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.04 - 7.37
52 week 6.71 - 16.87
Open 7.26
Vol / Avg. 2.11M/2.50M
Mkt cap 1.01B
P/E     -
Div/yield     -
EPS -0.79
Shares 136.39M
Beta 2.05
Inst. own 82%
Nov 2, 2015
Q3 2015 Achillion Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Sep 17, 2015
Achillion Pharmaceuticals Inc at Morgan Stanley Healthcare Conference - 10:35AM EDT - Add to calendar
Sep 9, 2015
Achillion Pharmaceuticals Inc at Robert W Baird and Co Health Care Conference - 12:15PM EDT - Add to calendar
Aug 10, 2015
Q2 2015 Achillion Pharmaceuticals Inc Earnings Release
Jun 23, 2015
Achillion Pharmaceuticals Inc at JMP Securities Life Sciences Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -4075.67% -
Operating margin -4105.20% -
EBITD margin - -
Return on average assets -42.61% -43.23%
Return on average equity -45.77% -46.56%
Employees 67 -
CDP Score - -

Address

300 George St
NEW HAVEN, CT 06511-6624
United States - Map
+1-203-6247000 (Phone)
+1-203-6247003 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on developing short-duration combination therapies for the treatment of chronic hepatitis C virus, or HCV, infection that are once-daily and ribavirin-free. The Company is advancing several combination regimens, including ACH-3102, a NS5A inhibitor, which is under Phase II clinical development, ACH-3422, a NS5B nucleotide polymerase inhibitor, which is under Phase I clinical development, and Sovaprevir, a NS3 protease inhibitor, which is under Phase II clinical development.

Officers and directors

David I. Scheer Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Milind S. Deshpande Ph.D. President, Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Mary Kay Fenton CPA Chief Financial Officer, Senior Vice President
Age: 51
Bio & Compensation  - Reuters
David Apelian M.D., Ph.D. Executive Vice President, Chief Medical Officer
Age: 49
Bio & Compensation  - Reuters
Joseph Truitt Executive Vice President, Chief Commercial Officer
Age: 50
Bio & Compensation  - Reuters
Michael D. Kishbauch Director
Age: 66
Bio & Compensation  - Reuters
Jason S. Fisherman M.D. Independent Director
Age: 58
Bio & Compensation  - Reuters
Gary E. Frashier Independent Director
Age: 78
Bio & Compensation  - Reuters
Kurt C. Graves Independent Director
Age: 47
Bio & Compensation  - Reuters
Robert L. Van Nostrand Independent Director
Age: 58
Bio & Compensation  - Reuters